Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort
Article first published online: 4 JUL 2007
Acta Neurologica Scandinavica
Volume 116, Issue 4, pages 207–210, October 2007
How to Cite
Greeve, I., Sellner, J., Lauterburg, T., Walker, U., Rösler, K. M. and Mattle, H. P. (2007), Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort. Acta Neurologica Scandinavica, 116: 207–210. doi: 10.1111/j.1600-0404.2007.00872.x
- Issue published online: 4 JUL 2007
- Article first published online: 4 JUL 2007
- Accepted for publication March 12, 2007
- clinically isolated syndrome;
- multiple sclerosis;
- anti-myelin oligodendrocyte glycoprotein;
- anti-myelin basic protein;
- Swiss cohort
Objectives – In patients with a clinically isolated syndrome (CIS), the time interval to convert to clinically definite multiple sclerosis (CDMS) is highly variable. Individual and geographical prognostic factors remain to be determined. Whether anti-myelin antibodies may predict the risk of conversion to CDMS in Swiss CIS patients of the canton Berne was the subject of the study.
Methods – Anti-myelin oligodendrocyte glycoprotein and anti-myelin basic protein antibodies were determined prospectively in patients admitted to our department.
Results – After a mean follow-up of 12 months, none of nine antibody-negative, but 22 of 30 antibody-positive patients had progressed to CDMS. β-Interferon treatment delayed the time to conversion from a mean of 7.4 to 10.9 months.
Conclusions – In a Swiss cohort, antibody-negative CIS patients have a favorable short-term prognosis, and antibody-positive patients benefit from early treatment.